Lorundrostat - Mineralys Therapeutics
Alternative Names: MLS-101; MT-4129Latest Information Update: 10 Apr 2025
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Mineralys Therapeutics; Mitsubishi Tanabe Pharma Corporation
- Class Acetamides; Amides; Antihypertensives; Benzene derivatives; Cardiovascular therapies; Cyclohexylamines; Small molecules; Triazines; Urologics
- Mechanism of Action Aldosterone synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypertension
- Phase II Renal failure
- No development reported Cardiovascular disorders
Most Recent Events
- 29 Mar 2025 Adverse events and efficacy data from a phase II ADVANCE-HTN trial in Hypertension released by Mineralys Therapeutics
- 10 Mar 2025 Adverse events and efficacy data from a phase II ADVANCE-HTN trial in Hypertension released by Mineralys Therapeutics
- 10 Mar 2025 Adverse events and efficacy data from a phase II LAUNCH-HTN trial in Hypertension released by Mineralys Therapeutics